NVCT (Nuvectis Pharma) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Change In Receivables?

Nuvectis Pharma's change in receivables for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Nuvectis Pharma's Accounts Receivable stayed the same from Jun. 2024 to Sep. 2024 .

Nuvectis Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Nuvectis Pharma's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Nuvectis Pharma's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nuvectis Pharma's liquidation value for the three months ended in Sep. 2024 was $10.85 Mil.

Nuvectis Pharma Change In Receivables Historical Data

The historical data trend for Nuvectis Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Change In Receivables Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Nuvectis Pharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial										-	-	-	-	-

Nuvectis Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Nuvectis Pharma (NAS:NVCT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nuvectis Pharma's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Nuvectis Pharma's accounts receivable are only considered to be worth 75% of book value:

Nuvectis Pharma's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	17.169	-	6.316	+	0.75 * 0	+	0.5 * 0
=	10.85

Nuvectis Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Executives

Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024